Expert review of anticancer therapy

Keyphrases

Publications

volume 23, number 2, 2023

Riccardo Ray Colciago, Irene Fischetti, Carlotta Giandini, Eliana La Rocca, Tiziana Rancati T, Alicia Rejas Mateo, Mario Paolo Colombo, Laura Lozza, Claudia Chiodoni, Elena Jachetti, Maria Carmen De Santis
Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement. Expert review of anticancer therapy 23 (2) (2023)
Wenjian Zhang, Lushan Zhou, Jianzhong Di
Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis. Expert review of anticancer therapy 23 (2) (2023)
Jonathan J Chen, Emily Weg, Jay J Liao
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope? Expert review of anticancer therapy 23 (2) (2023)
Maria Lia Palomba, Paola Ghione, Anik R Patel, Myrna Nahas, Sara Beygi, Anthony J Hatswell, Steve Kanters, Eve H Limbrick-Oldfield, Sally W Wade, Markqayne D Ray, Jessica Owen, Sattva S Neelapu, John Gribben, John Radford, Sabela Bobillo
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Expert review of anticancer therapy 23 (2) (2023)
Jayson Kemble, Eugene D Kwon, R Jeffrey Karnes
Addressing the need for more therapeutic options in neuroendocrine prostate cancer. Expert review of anticancer therapy 23 (2) (2023)
Jonathan Shamash, Kenrick Ng
Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors? Expert review of anticancer therapy 23 (2) (2023)

volume 23, number 3, 2023

Georg Schlachtenberger, Fabian Doerr, Hruy Menghesha, Andres Amorin, Katja Hoepker, Lars Hagmeyer, Thorsten Wahlers, Khosro Hekmat, Matthias B Heldwein
Prognostic impact of lymph node spreading pattern in N2 NSCLC patients. Expert review of anticancer therapy 23 (3) (2023)
Bernardo Stefanini, Luca Ielasi, Rusi Chen, Chiara Abbati, Matteo Tonnini, Francesco Tovoli, Alessandro Granito
TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert review of anticancer therapy 23 (3) (2023)
Stefano Lucà, Giuseppa Zannini, Floriana Morgillo, Carminia Maria Della Corte, Alfonso Fiorelli, Federica Zito Marino, Severo Campione, Giovanni Vicidomini, Gianluca Guggino, Andrea Ronchi, Marina Accardo, Renato Franco
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems. Expert review of anticancer therapy 23 (3) (2023)
Stefano Lucà, Giuseppa Zannini, Floriana Morgillo, Carminia Maria Della Corte, Alfonso Fiorelli, Federica Zito Marino, Severo Campione, Giovanni Vicidomini, Gianluca Guggino, Andrea Ronchi, Marina Accardo, Renato Franco
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems. Expert review of anticancer therapy 23 (3) (2023)
Maryam Noori, Farimah Fayyaz, Nima Rezaei
Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis. Expert review of anticancer therapy 23 (3) (2023)
Laureline Wetterwald, Nicolò Riggi, Anastasios Kyriazoglou, Giovanni Dei Tos, Angelo Dei Tos, Antonia Digklia
Clear cell sarcoma: state-of-the art and perspectives. Expert review of anticancer therapy 23 (3) (2023)
Jiajia Li, Yubo Xu, Jie Zhang, Shaohai Wang, Xiaoyu Wang, Huayan Guo, Guojun Miao
Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis. Expert review of anticancer therapy 23 (3) (2023)
Zachary J Brown, Samantha M Ruff, Timothy M Pawlik
Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy. Expert review of anticancer therapy 23 (3) (2023)
Laureline Wetterwald, Nicolò Riggi, Anastasios Kyriazoglou, Giovanni Dei Tos, Angelo Dei Tos, Antonia Digklia
Clear cell sarcoma: state-of-the art and perspectives. Expert review of anticancer therapy 23 (3) (2023)
Stefano Lucà, Giuseppa Zannini, Floriana Morgillo, Carminia Maria Della Corte, Alfonso Fiorelli, Federica Zito Marino, Severo Campione, Giovanni Vicidomini, Gianluca Guggino, Andrea Ronchi, Marina Accardo, Renato Franco
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems. Expert review of anticancer therapy 23 (3) (2023)
Bernardo Stefanini, Luca Ielasi, Rusi Chen, Chiara Abbati, Matteo Tonnini, Francesco Tovoli, Alessandro Granito
TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert review of anticancer therapy 23 (3) (2023)
Seyed Aria Nejadghaderi, Maryam Balibegloo, Maryam Noori, Farimah Fayyaz, Amene Saghazadeh, Nima Rezaei
Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis. Expert review of anticancer therapy 23 (3) (2023)
Zachary J Brown, Samantha M Ruff, Timothy M Pawlik
Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy. Expert review of anticancer therapy 23 (3) (2023)
Jerusha Padayachee, Simone Chaudhary, Brian Shim, Jonathan So, Remy Lim, Srinivas Raman
Utilizing clinical, pathological and radiological information to guide postoperative radiotherapy in prostate cancer. Expert review of anticancer therapy 23 (3) (2023)
Georg Schlachtenberger, Fabian Doerr, Hruy Menghesha, Andres Amorin, Katja Hoepker, Lars Hagmeyer, Thorsten Wahlers, Khosro Hekmat, Matthias B Heldwein
Prognostic impact of lymph node spreading pattern in N2 NSCLC patients. Expert review of anticancer therapy 23 (3) (2023)
Maryam Noori, Farimah Fayyaz, Nima Rezaei
Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis. Expert review of anticancer therapy 23 (3) (2023)
Jerusha Padayachee, Simone Chaudhary, Brian Shim, Jonathan So, Remy Lim, Srinivas Raman
Utilizing clinical, pathological and radiological information to guide postoperative radiotherapy in prostate cancer. Expert review of anticancer therapy 23 (3) (2023)
Deniz Can Guven, Hasan Cagrı Yıldırım, Elvin Chalabiyev, Fatih Kus, Feride Yilmaz, Serkan Yasar, Arif Akyildiz, Burak Yasin Aktaş, Suayib Yalcin, Omer Dizdar
Emerging treatment strategies in hepatobiliary cancer. Expert review of anticancer therapy 23 (3) (2023)
Zachary J Brown, Samantha M Ruff, Timothy M Pawlik
Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy. Expert review of anticancer therapy 23 (3) (2023)
Sebastiano Mercadante
Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review. Expert review of anticancer therapy 23 (3) (2023)
Deniz Can Guven, Hasan Cagrı Yıldırım, Elvin Chalabiyev, Fatih Kus, Feride Yilmaz, Serkan Yasar, Arif Akyildiz, Burak Yasin Aktaş, Suayib Yalcin, Omer Dizdar
Emerging treatment strategies in hepatobiliary cancer. Expert review of anticancer therapy 23 (3) (2023)
Jiajia Li, Yubo Xu, Jie Zhang, Shaohai Wang, Xiaoyu Wang, Huayan Guo, Guojun Miao
Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis. Expert review of anticancer therapy 23 (3) (2023)
Jiajia Li, Yubo Xu, Jie Zhang, Shaohai Wang, Xiaoyu Wang, Huayan Guo, Guojun Miao
Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis. Expert review of anticancer therapy 23 (3) (2023)
Bernardo Stefanini, Luca Ielasi, Rusi Chen, Chiara Abbati, Matteo Tonnini, Francesco Tovoli, Alessandro Granito
TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert review of anticancer therapy 23 (3) (2023)
Sebastiano Mercadante
Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review. Expert review of anticancer therapy 23 (3) (2023)
Laureline Wetterwald, Nicolò Riggi, Anastasios Kyriazoglou, Giovanni Dei Tos, Angelo Dei Tos, Antonia Digklia
Clear cell sarcoma: state-of-the art and perspectives. Expert review of anticancer therapy 23 (3) (2023)
Deniz Can Guven, Hasan Cagrı Yıldırım, Elvin Chalabiyev, Fatih Kus, Feride Yilmaz, Serkan Yasar, Arif Akyildiz, Burak Yasin Aktaş, Suayib Yalcin, Omer Dizdar
Emerging treatment strategies in hepatobiliary cancer. Expert review of anticancer therapy 23 (3) (2023)
Georg Schlachtenberger, Fabian Doerr, Hruy Menghesha, Andres Amorin, Katja Hoepker, Lars Hagmeyer, Thorsten Wahlers, Khosro Hekmat, Matthias B Heldwein
Prognostic impact of lymph node spreading pattern in N2 NSCLC patients. Expert review of anticancer therapy 23 (3) (2023)
Seyed Aria Nejadghaderi, Maryam Balibegloo, Maryam Noori, Farimah Fayyaz, Amene Saghazadeh, Nima Rezaei
Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis. Expert review of anticancer therapy 23 (3) (2023)
Zachary J Brown, Samantha M Ruff, Timothy M Pawlik
Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy. Expert review of anticancer therapy 23 (3) (2023)
Sebastiano Mercadante
Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review. Expert review of anticancer therapy 23 (3) (2023)
Seyed Aria Nejadghaderi, Maryam Balibegloo, Maryam Noori, Farimah Fayyaz, Amene Saghazadeh, Nima Rezaei
Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis. Expert review of anticancer therapy 23 (3) (2023)
Jerusha Padayachee, Simone Chaudhary, Brian Shim, Jonathan So, Remy Lim, Srinivas Raman
Utilizing clinical, pathological and radiological information to guide postoperative radiotherapy in prostate cancer. Expert review of anticancer therapy 23 (3) (2023)
Maryam Noori, Farimah Fayyaz, Nima Rezaei
Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis. Expert review of anticancer therapy 23 (3) (2023)

volume 23, number 6, 2023

Silvia Pecere, Cristina Ciuffini, Michele Francesco Chiappetta, Lucio Petruzziello, Luigi Giovanni Papparella, Cristiano Spada, Antonio Gasbarrini, Federico Barbaro
Increasing the accuracy of colorectal cancer screening. Expert review of anticancer therapy 23 (6) (2023)
Sara Pedretti, Maria Carmen De Santis, Vittorio Vavassori, Barbara Bortolato, Riccardo Ray Colciago, Emanuela Cagna, Daniela Patrizia Doino, Alessandra Cocchi, Marianna Alessandra Gerardi, Daniela Alterio, Stefano Maria Magrini, Sandro Tonoli
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy). Expert review of anticancer therapy 23 (6) (2023)
Qi-Ming Zheng, Yuan-Yuan Li, Ye-Peng Wang, Guo-Xiang Li, Meng-Meng Zhao, Zhi-Gang Sun
Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis. Expert review of anticancer therapy 23 (6) (2023)
Jane E Rogers, Kohei Yamashita, Matheus Sewastjanow-Silva, Ernesto Rosa Vicentini, Rebecca Waters, Jaffer A Ajani
Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma. Expert review of anticancer therapy 23 (6) (2023)
Giacomo Nuvola, Matteo Santoni, Mimma Rizzo, Matteo Rosellini, Veronica Mollica, Alessandro Rizzo, Andrea Marchetti, Nicola Battelli, Francesco Massari
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer. Expert review of anticancer therapy 23 (6) (2023)
Mohammad Atiq, Elias A Chandran, Fatima Karzai, Ravi A Madan, Jeanny B Aragon-Ching
Emerging treatment options for prostate cancer. Expert review of anticancer therapy 23 (6) (2023)
Michael Wotman, Adel El-Naggar, Renata Ferrarotto
Targeting human EGFR 2 (HER2) in salivary gland carcinoma. Expert review of anticancer therapy 23 (6) (2023)
Boris G Naraev, Josh Mailman, Thorvardur R Halfdanarson, Heloisa P Soares, Erik S Mittra, Julie Hallet
Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors. Expert review of anticancer therapy 23 (6) (2023)
Daniel G Sur, Cristina Lungulescu, Elena Adriana Dumitrescu, Vlad Afrăsânie, Ștefan Spînu, Cristian Virgil Lungulescu, Hans-Joachim Schmoll
A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer. Expert review of anticancer therapy 23 (6) (2023)
Tharani Krishnan, Fiona Wang, Chris Karapetis, Amitesh Roy, Timothy Jay Price
Primary site and treatment impact in unresectable metastatic colorectal cancer. Expert review of anticancer therapy 23 (6) (2023)